Regulation of transcription and tumor suppression by MTG family members
Regulation of transcription and tumor suppression by MTG family members
批准号:
9055662
负责人:
SCOTT W HIEBERT
金额:
$36.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-13 至 2019-04-30
关键词:
Acute Myelocytic LeukemiaAddressAffectAtlasesBindingC-terminalCBFA2T1 geneChimeric ProteinsChromatinChromosomal translocationChromosomes, Human, Pair 16Chromosomes, Human, Pair 8Colon CarcinomaComplexDNA Binding DomainDNA MethylationDNA Polymerase IIDataDevelopmentE proteinElongation FactorEnzymesEventFamily memberGene ActivationGene ExpressionGene FamilyGene ProteinsGenesGeneticGenetic TranscriptionGenomeHealthHistonesHodgkin DiseaseLengthLinkMLL geneMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryModelingMusMutateMutationMyelogenousN-terminalNCOR1 geneNCOR2 genePhenotypePhysiologicalPoint MutationProteomicsRNARNA SplicingRUNX1 geneRecruitment ActivityRegulationRoleSolid NeoplasmTAL1 geneTCF3 geneTestingThe Cancer Genome AtlasTranscription ElongationTranscriptional Elongation FactorsTranscriptional RegulationTumor SuppressionVariantWorkYeastsgene repressiongene translocationglobal run on sequencinghistone methyltransferasein vivoinnovationleukemialeukemogenesismalignant breast neoplasmmouse modelmutantnovelnovel strategiesrelease factorresearch studyt(821)(q22q22)transcription factortumortumorigenesisyeast two hybrid system
中文摘要
描述(申请人提供):两个髓系易位基因(MTG)家族成员MTG8和MTG16在急性髓系白血病中被染色体易位破坏。此外,癌症基因组图谱(TCGA)和其他大型测序研究发现了散布在整个基因体的MTG家族成员的突变,这表明这些突变可能是失活的突变。与这一解释一致,MTG16在霍奇金淋巴瘤中受到DNA甲基化的影响,MTG16和MTGR1在结肠癌中表达不足。我们的初步数据支持这一假设,因为在三种不同的癌症小鼠模型中,失活突变加速了肿瘤的发生。从机制上讲,MTG家族成员通过与CDK9和Tif1(或“月光”)的关联,在RNA Pol II停顿和延长水平上与转录控制密切相关。我们的初步数据显示,MTG家族成员直接与转录延长机制的关键调节因子接触,以负向调节基因表达。重要的是,MTG家族成员的癌症相关突变通过延长因子影响这些接触。因此,我们假设MTG依赖的转录暂停/延长调节是肿瘤抑制中的一个关键事件,这种负调控的释放允许转录暂停控制的基因激活。通过使用遗传学和创新的新方法(如全局运行转录测序)来定义MTGs调节转录延长的机制,以及通过使用肿瘤发生的小鼠模型,我们将直接检验这一假说,并定义在暂停和延长水平上转录控制的丧失如何促进肿瘤的发展。
英文摘要
DESCRIPTION (provided by applicant): Two myeloid translocation gene (MTG) family members, MTG8 and MTG16 are disrupted by chromosomal translocations in acute myeloid leukemia. In addition, the caner genome atlas (TCGA) and other large sequencing studies have identified mutations in MTG family members that are scattered throughout the gene body, suggesting that these may be inactivating mutations. Consistent with this interpretation, MTG16 is affected by DNA methylation in Hodgkin's lymphoma and MTG16 and MTGR1 are under expressed in colon cancer. Our preliminary data support this hypothesis in that inactivating mutations accelerated tumorigenesis in three separate mouse models of cancer. Mechanistically, MTG family members have been tangentially linked to transcriptional control at the level of RNA Pol II pausing and elongation through associations with CDK9 and Tif1 (or "Moonshine"). Our preliminary data shows that MTG family members make direct contacts with key regulators of the transcriptional elongation machinery to negatively regulate gene expression. Importantly, cancer associated mutations of MTG family members affect these contacts with elongation factors. Thus, we hypothesize that MTG-dependent regulation of transcriptional pausing/elongation is a key event in tumor suppression and that release of this negative regulation allows activation of genes controlled by transcriptional pausing. By defining the mechanism by which MTGs regulate transcriptional elongation using genetics and innovative new approaches such as global run on transcription sequencing, and by using mouse models of tumorigenesis, we will directly test this hypothesis and define how loss of transcriptional control at the level of pausing and elongation contributes to tumor development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
-
批准号:10445091
-
项目类别:
-
资助金额:$42.29万
-
财政年份:2021
-
负责人:SCOTT W HIEBERT
-
依托单位:
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
-
批准号:10298288
-
项目类别:
-
资助金额:$45.72万
-
财政年份:2021
-
负责人:SCOTT W HIEBERT
-
依托单位:
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
-
批准号:10652591
-
项目类别:
-
资助金额:$42.26万
-
财政年份:2021
-
负责人:SCOTT W HIEBERT
-
依托单位:
Regulation of transcription and tumor suppression by MTG family members
-
批准号:8696545
-
项目类别:
-
资助金额:$36.36万
-
财政年份:2014
-
负责人:SCOTT W HIEBERT
-
依托单位:
Regulation of transcription and tumor suppression by MTG family members
-
批准号:9265416
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2014
-
负责人:SCOTT W HIEBERT
-
依托单位:
FASEB SRC on HDACs, Sirtuins and Reversible Acetylation in Signaling and Disease
-
批准号:8595760
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2013
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8607465
-
项目类别:
-
资助金额:$39.1万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
-
批准号:9924498
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8230922
-
项目类别:
-
资助金额:$40.45万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8431792
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
-
批准号:10162514
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8791883
-
项目类别:
-
资助金额:$40.31万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
-
批准号:10406170
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8447369
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:7889851
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8068821
-
项目类别:
-
资助金额:$37.52万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8217259
-
项目类别:
-
资助金额:$37.47万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8615915
-
项目类别:
-
资助金额:$36.1万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Function of MTG16/ETO2 in acute leukemia
-
批准号:7798492
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2007
-
负责人:SCOTT W HIEBERT
-
依托单位:
Function of MTG16/ETO2 in acute leukemia
-
批准号:7393198
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2007
-
负责人:SCOTT W HIEBERT
-
依托单位:
海外基金